Recursion Pharmaceuticals
RXRX
199 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 70 increasing their positions, 48 reducing their positions, and 34 closing their positions.
105% more call options, than puts
Call options by funds: $8.93M | Put options by funds: $4.34M
77% more capital invested
Capital invested by funds: $1.16B → $2.06B (+$898M)
46% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 48
26% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 34
25.8% more ownership
Funds ownership: 74.62% → 100.42% (+26%)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
4% more funds holding
Funds holding: 192 → 199 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$98.2M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$40.5M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$40.5M |
| 4 |
Morgan Stanley
New York
|
+$31M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
-$8.01M |
| 2 |
Millennium Management
New York
|
-$5.04M |
| 3 |
JP Morgan Chase
New York
|
-$4.09M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$3.07M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$2.65M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAG
226
Private Advisor Group
Morristown,
New Jersey
| – | -$79K | -10,326 | Closed |
|
227
Allspring Global Investments
Charlotte,
North Carolina
| – | -$77.4K | -10,123 | Closed |
|
228
Belvedere Trading
Chicago,
Illinois
| – | -$48.5K | -6,340 | Closed |
|
229
Group One Trading
Chicago,
Illinois
| – | -$44.4K | -6,229 | Closed |
|
|
HGERS
230
Householder Group Estate & Retirement Specialist
Scottsdale,
Arizona
| – | -$2.85K | -400 | -97% |
|
|
CG
231
Cutler Group
San Francisco,
California
| – | -$713 | -100 | Closed |
|
232
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$566 | -74 | Closed |
|
|
C
233
Covestor
London,
United Kingdom
| – | -$14 | -2 | -13% |
|
RXRX Hedge Fund Activity: Q4 2023 in Review
199 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2023, worth a combined $2.06B — up 77% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new RXRX positions and 34 closed out — a net gain of 9 holders — while 70 added to existing stakes and 48 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $98.2M. The largest seller was ArchPoint Investors, exiting entirely with an estimated $8.01M sold.
- 199 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2023, up from 192 in Q3 2023.
- Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2023, up 77% quarter-over-quarter.
- 43 funds opened new Recursion Pharmaceuticals positions in Q4 2023 and 34 closed out, a net change of +9 holders.
- The largest Recursion Pharmaceuticals buyer in Q4 2023 was ARK Investment Management, an estimated $98.2M added.
- The largest Recursion Pharmaceuticals seller in Q4 2023 was ArchPoint Investors, an estimated $8.01M sold.
Based on aggregated 13F filings for Q4 2023.